研報掘金丨東吳證券:博瑞醫藥管線逐步進入臨牀階段,上調評級至“買入”評級
東吳證券研報指出,博瑞醫藥的雙靶點GLP-1/GIP受體激動劑BGM0504片IND申請已獲受理。注射劑數據珠玉在前,口服同樣具備BIC潛力。Amylin潛力巨大且競爭格局良好,公司管線具備潛在聯用可能性。BGM1812為一種長效胰澱素(amylin)類似物,目前處於臨牀前階段。目前唯一上市的amylin 藥物為阿斯利康的普蘭林肽,僅獲批糖尿病適應症,減重處在2期臨牀。BGM1812 能夠聯用公司現有的BGM0504,參考cagrisema,有望實現更佳的療效和公司產品內部的協同。考慮到公司管線逐步進入臨牀階段,確定性增加,上調公司評級至“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.